

Supplementary Figure S3. Photopic b-wave amplitudes of treated mutant mice and histological analysis of the periphery following 7m8.hCLN3 treatment. Photopic b-wave amplitudes of $Cln3^{\Delta ex7/8}$ mice that received intravitreal injections with 7m8.CMV.hCLN3 (**A**) and 7m8.Grm6.hCLN3 (**B**) at 12 and 15 months. 7m8.CMV.hCLN3 treatment resulted in significantly increased photopic b-wave amplitudes at 15 months, while 7m8.Grm6.hCLN3 treatment did not lead to higher b-wave amplitudes. Wild-type recordings from Fig. 1were added as a reference. For *n* numbers see Figs. 3 and 4, respectively. Two-way ANOVA with Bonferroni test (**p < 0.01). (**C**) Representative images of the peripheral retina of untreated, 7m8.CMV.hCLN3-, and 7m8.Grm6.hCLN3-treated mutant mice at 15 months. The number of PKC α -positive cells is increased in the treated compared with the untreated retinas. Scale bar: 25 μ m. hCLN3, human CLN3.

Supplementary Table S1.	Summary of scotopic b-wave	amplitudes in Cln3 ^{∆ex7/8}	³ mice that received intravitreal	and subretinal injectior
-------------------------	----------------------------	--------------------------------------	--	--------------------------

Mouse strain	AAV treatment	Titer (vg/eye)	Scotopic b-wave amplitudes (mean±SD)	
			12 Months	15 Months
Cln3 ^{∆ex7/8}	7m8.CMV.CIn3-ires-eGFP	1×10 ⁹	281.2 ± 48.4	192.3±40.4
$CIn3^{\Delta ex7/8}$	7m8.CMV.CIn3-ires-eGFP	1×10^{10}	278 ± 65.1	283.9 ± 52.5
CIn3 ^{∆ex7/8}	7m8.CMV.hCLN3	1×10^{10}	253 ± 51.3	251.4 ± 73.1
CIn3 ^{∆ex7/8}	7m8.Grm6.hCLN3	1×10^{9}	204.5 ± 60	186.3 ± 67.4
$CIn3^{\Delta ex7/8}$	7m8.Grm6.hCLN3	1×10^{10}	239.2 ± 60	206.6 ± 121
CIn3 ^{∆ex7/8}	7m8.CMV.eGFP	1×10^{10}	174.2±41.1	99.7 ± 27
$CIn3^{\Delta ex7/8}$	AAV8.CMV.mCIn3-ires-eGFP	1×10^{10}	175.2 ± 54.5	109.3 ± 55.1
$CIn3^{\Delta ex7/8}$	AAV8.CMV.eGFP	1×10^{10}	172 ± 61.5	93 ± 40.6
$CIn3^{\Delta ex7/8}$	_	_	154.5 ± 37.4	79.9±31.9
Wild type	_	—	327.6 ± 64	249.5 ± 51.3

Overview of the mean \pm SD of the scotopic b-wave amplitudes (at 1 cd.s/m²) in all AAV-treated mutant mice over time. Untreated mutant and wild-type controls were added as a reference from Fig. 2.

AAV, adeno-associated virus; CMV, cytomegalovirus; eGFP, enhanced green fluorescent protein; hCLN3, human CLN3; ires, internal ribosome entry site; SD, standard deviation.